Protracted treatment with tegafur and low dose oral leucovorin in patients with advanced colorectal carcinoma

Cancer

Volumn 83, Issue 2, 1998, Pages 254-258

  Nogué, Miquel ^a,f   Seguí, Miquel A ^a   Saigí, Eugeni ^a   Batiste Alentorn, Eduard ^b   Arcusa, Angels ^c   Boleda, Montserrat ^d   Antón, Isabel ^e  

^a Oncology Unit   (Spain)

^b HOSPITAL GENERAL DE VIC   (Spain)

^c HOSPITAL DE TERRASSA   (Spain)

^d Hospital Residencia Sant Camil   (Spain)

^e Hospital Sant Jaume de Calella   (Spain)

^f Unitat d'Oncologia   (Spain)

Author keywords

Biochemical modulation; Colorectal carcinoma; Leucovorin; Tegafur

Indexed keywords

FOLINIC ACID; TEGAFUR;

ADENOCARCINOMA; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; DIARRHEA; HUMAN; MUCOSA INFLAMMATION; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0032527659     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19980715)83:2<254::aid-cncr8>3.3.co;2-%23     Document Type: Article

References (20)

1. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992;10:896-903.
2. Brade WP, Herdrich K. Tegafur. A review of pharmacology and toxicology. Contr Oncol 1983;14:2-25.
3. Bedikian AY, Stroehlein J, Korinek J, Karlin D, Bodey GP. A comparative study of oral tegafur and intravenous 5-fluorouracil in patients with metastatic colorectal cancer. Am J Clin Oncol 1983;6:181-6.
4. Bjerkeset T, Fjosne HE. Comparison of oral ftorafur and intravenous 5-fluorouracil in patients with advanced cancer of the stomach, colon or rectum. Oncology 1986;43:212-5.
5. Andersen E, Pedersen H. Oral ftorafur versus intravenous 5-fluorouracil. A comparative study in patients with colorectal cancer. Acta Oncol 1987;26:433-6.
6. Schilsky RL, Choi KE, Vokes EE, Guaspari A, Guarnieri C, Whaling S, et al. Clinical pharmacology of the stereoisomers of leucovorin during repeated oral doses. Cancer 1989; 63(Suppl):1018-21.
7. Nogué M, Saigí E, Seguí MA. Clinical experience with tegafur and low dose oral leucovorin: a dose-finding study. Oncology 1995;52:167-9.
8. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
9. Creagan ET, Buckner JC, Hahn RG, Richardson RR, Schaid DJ, Kovach JS. An evaluation of recombinant leukocyte A interferon with aspirin in patients with metastatic renal cell cancer. Cancer 1988;61:1787-91.
10. Poon MA, O'Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989;7:1407-17.
11. Poon MA, O'Connell MJ, Wieand HS, Krook JE, Gerstner JB, Tschetter LK, et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991;9:1967-72.
12. Petrelli N, Douglass HO, Herrera L, Russell D, Stablein DM, Bruckner HW, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 1989;7:1419-26.
13. Jäger E, Heike M, Bernard H, Klein O, Bernhard G, Lautz D, et al. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. J Clin Oncol 1996;14:2274-9.
14. Buroker TR, O'Connell MJ, Wieand HS, Krook JE, Gerstner JB, Mailliard JA, et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994;12:14-20.
15. Rustum YM. Role of R,S-leucovorin dose and schedule in the therapeutic modulation of the efficacy and toxicity of fluoropyrimidines. Presented at: Proceedings of Leucovorin Modulation of Fluoropyrimidines, Amsterdam, the Netherlands, April 12, 1989.
16. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous-infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. J Clin Oncol 1989;7:425-32.
17. Rougier P, Buyse M, Ryan L, Hansen R, Zee B, Weinwrman B, et al. Meta-analysis of all trials comparing intravenous bolus administration to continuous infusion of 5-fluorouracil in patients with advanced colorectal cancer. Proc Annu Am Soc Clin Oncol 1997;16:A946.
18. Etienne MC, Guillot T, Milano G. Critical factors for optimizing the 5-fluorouracil-folinic acid association in cancer chemotherapy. Ann Oncol 1996;7:283-9.
19. Leichman CG, Fleming TR, Muggia FM, Tangem CM, Ardalan B, Doroshow JH, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 1995;13:1303-11.
20. Valone FH, Friedman MA, Wittlinger PS, Drakes T, Eisenberg PD, Malec M, et al. Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group. J Clin Oncol 1989; 7:1427-36.